TBXA2R - Thromboxane A2 receptor  | Elisa - Clia - Antibody - Protein

Background

The Thromboxane A2 Receptor (TBXA2R) is a G protein-coupled receptor (GPCR) primarily involved in mediating the effects of thromboxane A2 (TXA2), a lipid mediator derived from arachidonic acid metabolism. TBXA2R is a GPCR that responds to thromboxane A2 (TXA2), a potent vasoconstrictor and platelet aggregator synthesized by activated platelets and other cells. TBXA2R is expressed in various tissues and cell types, including platelets, vascular smooth muscle cells, endothelial cells, and immune cells. TBXA2R is activated by thromboxane A2 (TXA2), which is generated from arachidonic acid by the action of cyclooxygenase enzymes.

In summary, the Thromboxane A2 Receptor (TBXA2R) plays critical roles in mediating the physiological effects of thromboxane A2 (TXA2), including vasoconstriction, platelet aggregation, and inflammation. Dysregulation of TBXA2R signaling is implicated in cardiovascular diseases, thrombotic disorders, and inflammatory diseases, highlighting its therapeutic potential as a target for pharmacological intervention.

Structural Features:

• TBXA2R is a typical GPCR with seven transmembrane domains, an extracellular N-terminus, and an intracellular C-terminus.
• Ligand binding induces conformational changes in the receptor, leading to activation of downstream signaling pathways.

Physiological Functions:

• Vasoconstriction: TBXA2R activation mediates vasoconstriction in blood vessels, contributing to the regulation of blood pressure and blood flow.
• Platelet Aggregation: TBXA2R signaling induces platelet activation and aggregation, promoting hemostasis and thrombosis.
• Inflammation: Thromboxane A2 has pro-inflammatory effects, and TBXA2R activation may modulate immune cell function and cytokine production.

Clinical Implications:

• Cardiovascular Diseases: Dysregulation of TBXA2R signaling is implicated in cardiovascular diseases such as hypertension, atherosclerosis, and thrombosis.
• Thrombotic Disorders: Abnormal TBXA2R activation contributes to thrombotic disorders, including myocardial infarction, stroke, and deep vein thrombosis.
• Inflammatory Disorders: Altered TBXA2R expression or function may play a role in inflammatory diseases such as asthma and inflammatory bowel disease.

Therapeutic Potential:

• Antiplatelet Therapy: Inhibition of TBXA2R signaling pathways is a target for antiplatelet therapy to prevent thrombotic events.
• Vascular Protection: Modulation of TBXA2R activity may offer therapeutic strategies for the treatment of hypertension and vascular disorders.
• Anti-inflammatory Agents: Targeting TBXA2R signaling could be explored for the development of anti-inflammatory drugs for various inflammatory disorders.